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Abstract
Malaria is a global health problem that needs attention from drug discovery 
scientists to investigate novel compounds with high drug efficacy, safety and low 
cost to encounter the malaria parasites that are resistant to existing drug molecules. 
Antimalarial drug development follows several approaches, ranging from modifica-
tions of existing agents to the design of novel agents that act against novel targets. 
Most of market and clinical drugs act on blood schizonticide are in current therapy 
for malaria reduction. This chapter will intend to highlight the currently available 
drugs including various novel agents. In addition, emphasis has been given on the 
prospective pharmacophores that are likely to emerge as effective clinical candidates 
in the treatment of malaria. Besides all aspects, some alternative approaches will 
also be highlight.
Keywords: Antimalarial, drug resistance, current drug, Plasmodium, 
chemotherapeutic target
1. Introduction
Malaria is a prevalent infectious disease, affecting about 150 million people 
globally and responsible for around 4, 45,000 deaths annually [1]. Geographically, 
it is prevalent in 106 countries of the tropical and semitropical world. Africa 
accounts for 80% of total malaria cases and 90% global death. Malaria is caused 
by the apicomplexan protozoa Plasmodium genus which is transmitted from one to 
another through bitting by female Anopheles mosquito [2]. Five species are known 
to cause malaria fever in human i.e. P. vivax, P. falciparum, P.ovale, P. malariae and 
P. knowelsi [3, 4].
Among all plasmodium species, P. vivax is prevalent in central and South 
America, Asia [5]. P. ovale infections are rare and occur only in Africa i.e. <0.5% [6] 
P. malariae is present at the globe irregularly. P. falciparum is most fatal, because it 
produces large progeny in a short time and has the ability to cause cerebral malaria 
which is a severe complication and leads to death of the patient. Malaria has been 
a long-term health issue in world. In earlier 1960s to 1980s incidence of malaria 
prevalence have been highest, but now, there are several effort and projects handle 
by the international government to reverse malaria burden. Chemotherapy against 
the malaria parasite had been a vital component. However, resistance to existing 
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medicines is always a risk. Consequently, all treatments must be combinations of 
two or more active ingredients such that no compound is exposed as a monotherapy 
to high levels of parasites for a significant period of time wherever possible [7]. 
Artemisinin-based and nonartemisinin based combination with partner drug has 
been approved. This chapter will provides an overview of malaria, focusing on 
progress in drug discovery efforts, clinical development and the future highlight of 
malaria eradication agenda.
1.1 Malaria pathogenesis
Symptoms of malaria arose from hemozoin that released after rupture of 
infected RBCs. Hemozoin cause inflammation and take part in the immunogenic 
action in the blood which activates pro-inflammatory and anti-inflammatory 
cytokines [8]. Some studies have shown that IL-1B, IL-6, IL-8, and TNF-alpha 
increased in late-onset severe disease [9, 10]. Pathogenic phase of malaria is 
outcome of secreted cytokines tumor necrosis factor (TNF-α), interferon-γ 
(INF-γ), IL-6, IL-8, from macrophage and endothelial, and elevated level of 
as superoxide and nitric oxide (NO) [11]. These increased factor play role in 
dys-erythropoietic anemia, TNF-α may contribute to cerebral malaria through 
up-regulation of intracellular adhesion molecule-1 (ICAM-1) in cerebral blood 
vessel endothelium [12]. Pro-inflammatory cytokine induce cytokinemia and 
fever through interacting intracellularly with Toll-like receptor-9 (Figure 1), 
which lead to release of proinflammatory cytokines that can induce COX-2 up 
regulating prostaglandins [13, 14].
2. Diagnosis
Diagnosis of malaria infection in a patient is of critical importance since 
symptoms of complicated malaria may develop suddenly, causing the death of the 
patient. Clinical diagnosis based on the patient’s symptoms and on physical findings 
at examination
Figure 1. 
Schematic representation of malaria pathogenesis in the host cell.
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• Microscopic diagnosis parasite can be identified by examining under the 
microscope a drop of the patient’s blood, spread out as a “blood smear” on a 
microscope slide stained with Giemsa stain [15].
• A rapid diagnostic test based on antigen detection, this type of immuno-
logic test most often uses an antigen-coated dipstick which gives results in 
2–15 minutes. These “Rapid Diagnostic Tests” (RDTs) offer less time taking 
and more accurate results over microscopy [16, 17].
• Diagnosis of nuclei of the parasite through PCR (polymerase chain reaction) 
which is a quicker method [18].
• In serum-based diagnosis, malaria parasite responding antibodies generated 
in the human body can be detected indirectly by immunofluorescence (IFA) 
or enzyme-linked immunosorbent assay (ELISA). Serology can detect past 
exposure but unable to detect current infection [19].
3. Life cycle
Asexual Phase (Human) stage completed in humans after the invading 
of sporozoite to the liver which further infected other RBCs after parasitemia 
establishment. Sexual Phase (Mosquito) completed in the gut of mosquito [20]. 
When parasite bite infected humans, gametocytes occur in female and male form 
reach in their salivary gland and enter into the gut of the mosquito. The male and 
female gametes are fused in the gut of the mosquito to form zygotes [21]. After 
fertilization of gametes, ookinetes form which penetrates the gut epithelial cells 
and finally converts into an oocyst. The oocyst multiplies by asexual replication and 
produces sporozoites. Rupture of the mature oocyst releases the sporozoites into the 
hemocoel (body cavity) of the mosquito, from where they travel to the mosquito 
salivary glands [22]. When an infected mosquito has a blood meal, it injects saliva 
containing the parasite (sporozoites) into the human bloodstream, causing malaria 
infection in the new human host. Now the sporozoites travel through the circula-
tory system to the liver and invade hepatocytes, where the sporozoites multiply 
and grow through asexual replication known as exoerythrocytic schizogony. Each 
sporozoite develops into a schizont containing thousands of merozoites, which 
are released into the bloodstream. In the case of P. vivax and P. ovale, they live in 
a latent form in the liver-cell which can be dormant up to months or years. These 
hypnozoites relapse when a new primary infection reaches to liver cells [23]. The 
erythrocytic life cycle begins when free merozoites invade through erythrocytes. 
The erythrocytic cycle is responsible for all clinical manifestations of the disease. 
Merozoites invade erythrocytes by multiple receptor-ligands interactions within 
a few seconds. The early trophozoite is often called ‘ring form’ because of its 
morphology. Ring stage is developed into the trophozoite stage by metabolizing 
host cytoplasm and degradation of hemoglobin into globin and amino acids. The 
trophozoite is developed to schizont by multiple rounds of nuclear division without 
cytokinesis and produces 8–32 daughter merozoites [24, 25]. Mature merozoites 
came outside the red blood cell and released merozoites invade new RBCs and 
this cycle repeats. This blood stage cycle is responsible for the pathology related to 
malaria. Asexual stage converted into sexual stages i.e. male, female gametocyte 
[26, 27]. Which helps in the transmission of the infection to others through the 
female Anopheles mosquitoes, wherein they continue the sexual phase of the 
parasite’s life cycle.
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4. Treatment of malaria
This classification of candidate drugs is strictly based on the stage in which they 
exhibit their potency within the parasite life cycle. In this classification, drugs are 
divided into five major categories (Table 1) [28].
• Blood schizontocides: These drugs act on the blood stages of parasites and 
therefore prevent spreading out of malaria. The common members of this class 
include artemisinin (ART) and its derivatives, chloroquine (CQ ), quinine 
(QN), mefloquine (MQ ), halofantrine (HF), pyrimethamine and sulfadoxine.
• Tissue schizontocides for causal prophylaxis: These drugs act on the hypno-
zoites (liver forms of Plasmodium) occurring prior to the erythrocytic stage. 
These drugs are very important since they could prevent the onset and devel-
opment of clinical infection at the early stage of the disease, e.g. Primaquine 
(PQ ) and pyrimethamine.
• Tissue schizonticides for relapse prevention: These drugs act on the sporozo-
ites of P.vivax and P.ovale in host liver cells, which is responsible for the relapse 
of malaria symptoms and regeneration of the disease e.g. primaquine.
• Gametocytocidal: These drugs target the gametocyte of the parasite in the 
blood and also prevent the transmission parasitic stages to the mosquito. CQ 
and QN have gametocytocidal activity against P. vivax and P. malariae but not 
against P. falciparum, but ART has activity against P. falciparum. Primaquine 
found to suppress P. vivax as well as P. falciparum.
5. Drug resistance in P. falciparum
Drug resistance is the reduction in the effectiveness of a medication such as an 
antimicrobial or an antineoplastic in curing a disease or condition [29]. The term is 
used in the context of pathogen that acquired survival potential in presence of drug. 
When an organism is resistant to more than one drug, it is said to be multidrug 
resistant.
P. falciparum resistance to chloroquine and sulphadoxine–pyrimethamine 
first developed on the in Southeast Asia and South America in the late 1950s 
and 1960s, respectively. The spread of resistant parasite strains elsewhere, 
including Africa, have been well documented retrospectively with molecular 
markers of the resistance to each drug. Chloroquine has been replaced by the 
combination of sulphadoxine and pyrimethamine (SP) in 1973. SP is widely used 
antimalarial worldwide and also used as the first line of treatment for malaria 
alone or in combination with other antimalarial drugs. SP resistance also became 
a big challenge to malaria control programs. For tackling this problem, SP was 
replaced by mefloquine but resistance to this new drug developed very rapidly. 
Mefloquine resistance was first observed in the late 1980s again in the same 
endemic area near the Thai-Cambodian border which spread out to Southeast 
Asia, South America and some pockets in Africa [30]. Resistance to SP was first 
described from the Thai-Cambodian border [31]. After chloroquine and sulpha-
doxine–pyrimethamine failures, Thailand introduced mefloquine in place of SP. 
For tackling this problem, Thailand imposed strict controls on its use but meflo-
quine resistance was first observed in the late 1980s and early 1990s again in the 













Drug class Drug Target of action Mode of Action Clinical use
4-Aminoquanoline Chloroquine Blood-stage schizonticides Direct heme binding, Inhibit heme Fe(II) 
FPIX Polymerase
Treatment and chemoprophylaxis of sensitive 
parasites
Cinchona alkaloid Quinine Erythrocyte schizonticides Same as CQ Treatment of CQ-resistant P. falciparum
Quinoline-methanol Mefloquine Blood-stage schizonticides Formation of a toxic substance, Swelling of 
the food vacuole
Chemoprophylaxis and treatment of P. 
falciparum
8-Aminoquanoline Primaquine Tissue-stage schizonticides & 
gametocytocidales
Generation of toxic metabolites, Oxygen 
radicals in Plasmodial mitochondria
Radical cure and terminal prophylaxis of P. 
vivax & P. ovale
Amino alcohol Halofantrine/
Pyronaridine
Erythrocyticschizonticides Inhibit heme polymerase, inhibit vacuolar 
degradation
Treatment of CQ-resistant P. falciparum
Naphthoquinone Atovaquone Blood-stage schizonticides Inhibit mitochondrial electron transport Treatment and chemoprophyla xis of P. 





Blood-stage schizonticides Inhibitor of dhfr-ts/dhps, thereby, inhibit 
parasitic DNA
A headache. SJS, Skin rash Treatment of 
CQ-resistant P. falciparum (in combination as 
SP)
Biguanide Proguanil Erythrocyticschizonticides Inhibit dhfr and stops pyrimidine 
biosynthesis
Chemoprophyla xis (with CQ )
Tetracyclines Tetracycline/
Doxycyclin e
Blood-stage schizonticides Inhibit mitochondrial protein synthesis, block 
nucleic acid synthesis
Treatment and chemoprophyla xis of P. 
falciparum




Formation of iron catalyzed free radical, 
alkylation of heme, membrane damage by 
free radical
Treatment of multidrug-resistant P. falciparum
Table 1. 
Common antimalarial drugs and their mechanism of action.
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rate was reversed with the introduction of artemisinin. The introduction of the 
artemisinin saved millions of lives around the world [32]. Artemisinin leads to 
a high rate of recrudescence (reinfection of parasites) other drugs are required 
to clear the body of all parasites and prevent recurrence hence several more 
potent derivatives were synthesized viz., artesunate, arte-ether, arte-mether and 
dihydroartemisinin [33]. In 1995, Thailand replaced mefloquine with artesunate–
mefloquine. The same combination was the first-line therapy in Cambodia from 
2000 to 2012.
5.1 Resistance to artemisinin-based combination therapies
To linger off artemisinin resistance, treatment for malaria is given as artemisinin 
based combination therapy (ACTs) in place of artemisinin alone or its derivative 
to treat uncomplicated malaria. ACT must include 1 artemisinin or its derivative 
another is other antimalarial drug or compound as prescribed by WHO 2001. 
ACTs are more efficient medicine today that is available, as it has great potential; it 
replaced antifolates and quinoline drug class which was used as the first-line treat-
ment for P. falciparum.
Presently, artemisinin resistance is only prevalent in to the Cambodia, 
Thailand, Lao people’s Democratic Republic [34], Viet Nam, Myanmar, and the 
Myanmar-China-India border area. In 2006, the declined efficacy of ASMQ (arte-
sunate/mefloquine) was suspected for the first time on the Cambodia-Thailand 
border [35]. Thereafter, ASMQ clinical failures were reported on the Thailand-
Myanmar border in correlation with delayed parasite clearance time [36]. Reason 
for resistance toward artemisinin derivatives because it promotes selection for 
partner-drug resistance mainly due to mismatches in the pharmacokinetics of 
the two drugs, causing frequent treatment failure of ACTs [37], amplification 
of pfmdr1 gene copy numbers. Clinical failures after dihydroartemisinin-
piperaquine (DHA/PPQ ) treatment have been reported, first in Cambodia in 
2013 [38] and later in Vietnam in 2017 [39, 40] five and twelve years, respectively, 
after DHA/PPQ treatment introduction. DHA/PPQ resistance was confirmed by 
several reports and correlated with pfk13polymorphism, plasmepsin 2–3 gene 
amplification and single copies of the pfmdr1 gene [41]. Clinical failure rates 
greater than 10% have now been reported for the 5 ACTs in Cambodia, for 2 
ACTs in Thailand and Lao PDR and for 1 ACT in Viet Nam, Myanmar, and in the 
Chinese and Indian border regions with Myanmar. It has been demonstrated that 
plasmepsin 2–3 gene amplification in DHA/PPQ resistant parasites is associated 
with pfmdr1 gene single copies, so these resistant parasites are sensitive to meflo-
quine [42]. In contrast, ASMQ-resistant parasites with pfmdr1 gene amplification 
are sensitive to piperaquine [37]. Based on the amplification of pfmdr1 gene copy 
numbers of ACT-resistant parasites, the alternating use of ASMQ and DHA/PPQ 
is under consideration.
5.2 Potential chemotherapeutic target
Developing resistance toward antimalarial drug has tinted requirement of new 
compound with antimalarial activity. To overcome this problem new validated drug 
target needed with detailed study of biochemical and metabolic processes of the 
parasite [43]. One way is to search for new drug(s) which inhibit parasite growth 
and cure malaria, secondly to find ways to reverse drug resistance mechanism. 
Research over the years have identified a number of potential drug targets mainly 
proteins in the parasite that can be utilized as drug targets.
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6. Drug development research in during 2010–2019
There is continuous efforts has been given after resistance toward existing drug 
chloroquine, mefloquine, piperaquine, sulphadoxine-pyrimethamine, artemisinin 
derivatives, in Southeast Asia. Resistance to the partner drug, not artemisinin, 
is the primary driver for failure of ACT. Hence along with combination therapy 
of artemisinin second alternative drug is needed. Medicine of malaria venture is 
a non governmental organization which support collaborations with a library of 
antimalarial leads drug discovery (www.mmv.org.in). Clinically used antimalarial 
combination dose described in (Table 2).
A study of literature peformed to find out the new leads and their clinical 
stage along with survey on www.mmv.org, www.mpmp.huji, and ClinicalTrials. 
gov website (https://www.clinicaltrials.gov/). Major new drugs focus the blood 
schizonticide stage of uncomplicated P. falciparum. These potential inhibitor of 
plasmodium cycle must be single dose with minimum exposure and minimized 
toxicity in pregnant women and children with quite affordability to common 
people of minimum income.
There are at least 13 agents in clinical development (Table 3). Krintafel 
(tafenoquine) developed by Glaxosmith in collaboration with MMV has the 
potential to clear hypnozoites is approved for a single dose by regulatory authori-
ties as a treatment for Plasmodium vivax relapse prevention. This represents an 
advance over standard 14-day primaquine regimens; however, the risk of acute 
haemolytic anemia in patients with glucose-6-phosphate dehydrogenase defi-
ciency remains. Cipargamin (KAE609), developed by Novartis in collaboration 
with MMV. Cipargamin targets a cell membrane channel in the parasite, which is 
the new molecular target for malaria in more than 20 years. 75 mg for over 8 days 
require killing parasite in blood, and also having malaria transmission blocking. 
Intravenous formulation for severe malaria is also planned for 2020. One of the 
leading pipeline combinations are artefenomel (OZ439)–ferroquine and lumefan-
trine-KAF156, both in Phase 2b. Artefenomel is nonartemisinin based drug which 
has been designed by joint sanofi and mmv effort for children and to allow for once-
daily. The combination is currently in a phase IIb trial, which is completed in the 
2018. A novel trioxane 97/78, contains 1,2,4-trioxane nucleus similar to artemisinin 
developed by Central Drug Research Institute (CDRI), India, has shown promising 
antimalarial activity and is currently in clinical trials phase I. This 97/78 target, 
plasmodial phospholipid metabolism responsible for their pharmacological activity. 
Firstly 97/63 was synthesized but, due to its poor bioavailability, it was resynthe-
sized as a hemisuccinate derivative and coded as 97/78. Upon administration of 
97/78 it gets converted into its active in vivo metabolite 97/63. The concentrations of 
97/63 and 97/78 can be measured by validated LC–MS/MS method [44].
7. Conclusion
In last ten years of discovery and development of new anti-malarial medicines 
showed an explosion in new molecules in the malaria pipeline. These current leads 
are result of a dramatic increase in the number and diversity of new molecules 
presently in pre-clinical and early clinical development. MMV itself and along 
with collaboration make this discovery possible. When malaria remains a challenge 
because of drug failure resist toward current line therapies time to time in paral-
lele a successful drug discovery programmes also been run that provide satisfac-











Combinations Dosing schedule and summary Trade name/associated organization Year of Launching
Artemether-lumefantrine • Dosing twice/day for three days
• Qualified WHO prequalification in Feb 2009
• Approved from the US-FDA
• Several generic version of this have been produced.
(Coartem®/Novartis, MMV) 2008
Artesunate-amodiaquine • Dosing once/day for three days.
• Approved in 31 countries including 25 in Africa
• Prequalified in 2008 by WHO.
(Carsucam®; (Sanofi/DNDi/MMV) 2008
Artesunate-Mefloquine • It given once/day over three days.
• Prequalified by WHO in September 2012




Dihydroartemisinin-piperaquine • It given once/day for three days. Approved by EMA in 2011.
• Prequalified by WHO
• Included in the malaria treatment guidelines of WHO in 2011.
(Eurartesim®/Artekin®/sigma-Tau/MMV/Pfizer) 2010
Artesunate-Pyronaridine • It given once/day for three days
• Approved by the KFDA in 2011 and by the EMA in 2012.
• Prequalified by WHO.
(Pyramax®/ShingPoong/MMV) 2011
Table 2. 
Antimalarial combination along with prescribed dose.
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present, is in a state where we still have leads in final stage to be released at market 
level. Currently Tafenoquine is permit to use for P.vivax malaria. With the current 
scenario of drug development against malaria we are able to control the situation 
and in next year we will be on the path of control malaria eradication. In many 
countries encouraging progress toward malaria elimination achieved e.g. Sri Lanka, 
China. With new clinically approved agents (arterolane, cipargamin, KAF156) on 
the horizon show potential to replace failing artemisinin combination therapies as 
part of novel combinations. Malaria drug discovery studies are in the successive 
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